• Promising cancer drug development progress
• Collaboration with CSL for international conference presentation
• Recognition in Nature Reviews Rheumatology journal
• SOF-SKN manufacturing begins
• Engaged CRO for US regulatory strategy

Noxopharm Ltd provided its Quarterly Activities Report for the period ending 30 June 2026, highlighting promising progress in its cancer drug development program. The company announced new data showing how its Sofra technology platform will be leveraged to fight cancer, specifically targeting Toll-like receptor 8 (TLR8) against cancer. Noxopharm's assets will be highlighted at an international conference by CSL, a global biopharma company. Additionally, the company's breakthrough discovery was included in a new overview of global research in Nature Reviews Rheumatology. Noxopharm also announced the start of SOF-SKN manufacturing, involving a series of quality control tests. The company has engaged a CRO to support its US regulatory strategy.

Noxopharm Ltd expects to require additional funding to sustain R&D activities.

Noxopharm Ltd is exploring options to secure additional capital and is in discussions with potential funders.